• 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106-130.
  • 2
    Freeman HP, Muth BJ, Kerner JF. Expanding access to cancer screening and clinical follow-up among the medically underserved. Cancer Pract. 1995; 3: 19-30.
  • 3
    Underwood SM. Reducing the burden of cancer borne by African Americans: if not now, when? Cancer Epidemiol Biomarkers Prev. 2003; 12: 270s-276s.
  • 4
    Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst. 2009; 101: 984-992.
  • 5
    Thompson I, Tangen C, Tolcher A, Crawford E, Eisenberger M, Moinpour C. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst. 2001; 93: 219-225.
  • 6
    Fowler JE Jr, Terrell F. Survival in blacks and whites after treatment for localized prostate cancer. J Urol. 1996; 156: 133-136.
  • 7
    Zietman A, Moughan J, Owen J, Hanks G. The Patterns of Care Survey of radiation therapy in localized prostate cancer: similarities between the practice nationally and in minority-rich areas. Int J Radiat Oncol Biol Phys. 2001; 50: 75-80.
  • 8
    Roach M 3rd, Krall J, Keller JW, et al. The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group protocols (1976-1985). Int J Radiat Oncol Biol Phys. 1992; 24: 441-449.
  • 9
    Rosser CJ, Kuban DA, Lee SJ, et al. Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. J Natl Med Assoc. 2004; 96: 939-944.
  • 10
    Hamilton RJ, Aronson WJ, Presti JC Jr, et al. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer. 2007; 110: 2202-2209.
  • 11
    Powell IJ, Banerjee M, Novallo M, et al. Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease. Urology. 2000; 55: 246-251.
  • 12
    Zagars GK, Pollack A, Pettaway CA. Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation. Int J Radiat Oncol Biol Phys. 1998; 42: 517-523.
  • 13
    Nielsen ME, Han M, Mangold L, et al. Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. J Urol. 2006; 176: 515-519.
  • 14
    Moreira DM, Presti JC Jr, Aronson WJ, et al. The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. Prostate Cancer Prostatic Dis. 2010; 13: 87-93.
  • 15
    Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17: 1471-1474.
  • 16
    Mohler JL. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer [editorial]. J Natl Compr Canc Netw. 2010; 8: 145.
  • 17
    Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys. 2002; 52: 444-452.
  • 18
    Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2009; 75: 16-22.
  • 19
    Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965-974.
  • 20
    Asbell SO, Vijayakumar S. Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Prostate. 1997; 31: 42-46.
  • 21
    Vijayakumar S, Winter K, Sause W, et al. Prostate-specific antigen levels are higher in African-American than in white patients in a multicenter registration study: results of RTOG 94-12. Int J Radiat Oncol Biol Phys. 1998; 40: 17-25.
  • 22
    Stone NN, Stock RG, Cesaretti JA, Unger P. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys. 2010; 76: 355-360.
  • 23
    Kupelian PA, Buchsbaum JC, Patel C, et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys. 2002; 52: 704-711.
  • 24
    Roach M 3rd, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Grignon D. Race and survival of men treated for prostate cancer on Radiation Therapy Oncology Group phase III randomized trials. J Urol. 2003; 169: 245-250.
  • 25
    Sohayda CJ, Kupelian PA, Altsman KA, Klein EA. Race as an independent predictor of outcome after treatment for localized prostate cancer. J Urol. 1999; 162: 1331-1336.
  • 26
    Lee LN, Barnswell C, Torre T, Fearn P, Kattan M, Potters L. Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses. Int J Radiat Oncol Biol Phys. 2002; 53: 282-289.
  • 27
    Gaston KE, Kim D, Singh S, Ford OH 3rd, Mohler JL. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol. 2003; 170: 990-993.
  • 28
    Coetzee GA, Ross RK. Re: prostate cancer and the androgen receptor. J Natl Cancer Inst. 1994; 86: 872-873.
  • 29
    Powell IJ, Land SJ, Dey J, et al. The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy. Cancer. 2005; 103: 528-537.
  • 30
    Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther. 2000; 68: 82-91.
  • 31
    Paris PL, Kupelian PA, Hall JM, et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev. 1999; 8: 901-905.
  • 32
    Zeigler-Johnson C, Friebel T, Walker AH, et al. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res. 2004; 64: 8461-8467.
  • 33
    Powell IJ, Zhou J, Sun Y, et al. CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy. J Urol. 2004; 172( 5 pt 1): 1848-1852.
  • 34
    Roach M 3rd, De Silvio M, Rebbick T, et al. Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2007; 69: 79-87.